Garnet E. Peck, PhD
Garnet E. Peck, PhD
Professor Emeritus of
Industrial Pharmacy
Purdue University
Garnet E. Peck is a professor emeritus and visiting professor in the department of industrial and physical pharmacy at Purdue University’s School of Pharmacy and Pharmaceutical Sciences. He received his BS (1957) in pharmacy from Ohio Northern University and MS (1959) and PhD (1962) degrees in industrial pharmacy from Purdue University. From 1962 to 1967, Peck was employed by the Mead Johnson Research Center and in 1967 he returned to Purdue University to join the department of industrial and physical pharmacy. He was associate department head from 1989 to 1996.
Peck’s research interests include optimization of drug product design and process design, in particular those systems involving tablets, topical drug adsorption, flow of solid systems, dispersed systems design and evaluation, new tablet coating materials and procedures, and excipient-drug interaction. His research has resulted in more than 110 scientific publications.
Peck is a member of the APhA, the PT Section of the American Association of Pharmaceutical Scientists (AAPS), ACS, AACP, New York Academy of Science, Sigma Xi, Rho Chi, Phi Lambda Upsilon, Phi Kappa Phi and is a fellow of the AAAS, APRS, AAPS, and the American Institute of Chemists. Peck was chairman of the IPT Section of the Academy of Pharmaceutical Sciences for 1983-84. He was elected to the 1985-1990 United States Pharmacopeia Committee of Revision and then re-elected to the committee for 1990-1995 and 1995-2000. He was elected to the Committee of Experts, Excipients for 2000-2005. Peck is a founding member of The Catholic Academy of Science in the United States founded in 1987.
In March 1994, he was awarded by the American Pharmaceutical Association the Sidney L. Riegelman Research Achievement Award in Pharmaceutics, and he received the Pharmaceutical Technology Publishers’ Award in September 1994.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.